Anti-tumor activity of naive and activated class I-restricted tumor-specific TCR-transgenic T cells.

被引：0
|
作者：
Dalyot-Herman, N [1 ]
Malek, TR [1 ]
机构：
[1] Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33101 USA
来源：
FASEB JOURNAL | 1999年 / 13卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：A613 / A613
页数：1
相关论文
共 50 条
  • [21] DNA microarray analysis of the gene expression profiles of naive versus activated tumor-specific T cells
    Zhang, XS
    Chen, ZA
    Huang, H
    Gordon, JR
    Xiang, J
    LIFE SCIENCES, 2002, 71 (25) : 3005 - 3017
  • [22] Tumor-specific activated photodynamic therapy with an oxidation-regulated strategy for enhancing anti-tumor efficacy
    Liang, Huan
    Zhou, Zhanwei
    Luo, Renjie
    Sang, Mangmang
    Liu, Bowen
    Sun, Minjie
    Qu, Wei
    Feng, Feng
    Liu, Wenyuan
    THERANOSTICS, 2018, 8 (18): : 5059 - 5071
  • [23] Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models
    Takeda, Yohei
    Yoshida, Sumito
    Takashima, Ken
    Ishii-Mugikura, Noriko
    Shime, Hiroaki
    Seya, Tsukasa
    Matsumoto, Misako
    CANCER SCIENCE, 2018, 109 (07): : 2119 - 2129
  • [24] Tumor progression in immunocompetent mice despite the presence of activated tumor-specific T cells
    Brown, IE
    Yu, P
    Davis, M
    Shilyansky, J
    FASEB JOURNAL, 2001, 15 (04): : A661 - A661
  • [25] Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model
    Bruno, Tullia C.
    Rothwell, Cristin
    Grosso, Joseph F.
    Getnet, Derese
    Yen, Hung Rong
    Durham, Nicholas M.
    Netto, George
    Pardoll, Drew M.
    Drake, Charles G.
    PROSTATE, 2012, 72 (05): : 514 - 522
  • [26] Phosphorylated self-peptides alter human leukocyte antigen class I-restricted antigen presentation and generate tumor-specific epitopes
    Petersen, Jan
    Wurzbacher, Stephanie J.
    Williamson, Nicholas A.
    Ramarathinam, Sri H.
    Reid, Hugh H.
    Nair, Ashish K. N.
    Zhao, Anne Y.
    Nastovska, Roza
    Rudge, Geordie
    Rossjohn, Jamie
    Purcell, Anthony W.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (08) : 2776 - 2781
  • [27] Cytokines required for induction of histocompatibility leukocyte antigen-class I-restricted and tumor-specific cytotoxic T lymphocytes by a SART1-derived peptide
    Matsunaga, K
    Nakao, M
    Masuoka, K
    Inoue, Y
    Gouhara, R
    Imaizumi, T
    Nishizaka, S
    Itoh, K
    JAPANESE JOURNAL OF CANCER RESEARCH, 1999, 90 (09): : 1007 - 1015
  • [28] Go-TCR: Inducible MyD88/CD40 (iMC) Enhances Proliferation and Survival of Tumor-Specific TCR-Modified T Cells, Increasing Anti-Tumor Efficacy
    Hoang, Tsvetelina P.
    Foster, Aaron
    Rodriguez, Tania
    Torres, David
    Lu, An
    Crisostomo, Jeannette
    Jahn, Lorenz
    Heemskerk, Mirjam H. M.
    Spencer, David M.
    MOLECULAR THERAPY, 2016, 24 : S294 - S295
  • [29] ANTI-TUMOR EFFECTS OF AN ANTISERUM RAISED IN SYNGENEIC MICE TO A TUMOR-SPECIFIC T-SUPPRESSOR FACTOR
    MAIER, T
    LEVY, JG
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1982, 13 (02) : 134 - 139
  • [30] The development and functions of CD4+ T cells expressing a transgenic TCR specific for an MHC-I-restricted tumor antigenic epitope
    Xue Han
    Peiying Ye
    Liqun Luo
    Linghua Zheng
    Yang Liu
    Lieping Chen
    Shengdian Wang
    Cellular & Molecular Immunology, 2011, 8 : 333 - 340
12345